Antiphospholipid syndrome–an update
B Linnemann - Vasa, 2018 - econtent.hogrefe.com
Antiphospholipid syndrome (APS) is an autoantibody-mediated acquired thrombophilia. It is
characterized by the presence of antiphospholipid antibodies (APL) that are directed against …
characterized by the presence of antiphospholipid antibodies (APL) that are directed against …
Clinical relevance of isolated lupus anticoagulant positivity in patients with thrombotic antiphospholipid syndrome
D Yin, PG de Groot, M Ninivaggi… - Thrombosis and …, 2021 - thieme-connect.com
Background Patients positive for all three types of antiphospholipid antibodies (aPLs; triple
positivity) have been identified for having a high risk for thrombotic events. However, the …
positivity) have been identified for having a high risk for thrombotic events. However, the …
Comparison of the therapeutic effects of rivaroxaban versus warfarin in antiphospholipid syndrome: a systematic review
M Khodashahi, Z Rezaieyazdi… - Archives of …, 2019 - pmc.ncbi.nlm.nih.gov
Objectives This study aims to review the studies evaluating the therapeutic effects of
rivaroxaban versus those of warfarin in patients with antiphospholipid syndrome (APS) …
rivaroxaban versus those of warfarin in patients with antiphospholipid syndrome (APS) …
Inflammation, infections and immunity
H Alnwaisri - 2020 - flore.unifi.it
The title of thesis is inflammation, infections and immunity. It contains two researches, the
first research is Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult …
first research is Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult …
[引用][C] Sindrome Antifosfolipidoaren errebisio bibliografikoa: Basurtuko Unibertsitate Ospitaleko kasu baten inguruan.
J Zugaza Goienetxea - 2020